CO6170362A2 - Procedimiento de preparacion de halogenuros de n-alquil-naltrexona - Google Patents
Procedimiento de preparacion de halogenuros de n-alquil-naltrexonaInfo
- Publication number
- CO6170362A2 CO6170362A2 CO09028774A CO09028774A CO6170362A2 CO 6170362 A2 CO6170362 A2 CO 6170362A2 CO 09028774 A CO09028774 A CO 09028774A CO 09028774 A CO09028774 A CO 09028774A CO 6170362 A2 CO6170362 A2 CO 6170362A2
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- naltrexone
- carbonate
- double
- ion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1.- Ion doble de N-metil-naltrexona, de la fórmula:en el estado de forma anhidra o de hidrato. 2.- Ion doble de N-metil-naltrexona según la reivindicación 1, de configuración (R) con respecto al átomo de nitrógeno. 3.- Ion doble de N-metil-naltrexona según la reivindicación 1 de configuración (S) con respecto al átomo de nitrógeno. 4.- Ion doble de N-metil-naltrexona según una cualquiera de las reivindicaciones 1 a 3, en el estado de hidrato elegido entre el estado de hemihidrato, dihidrato y trihidrato.5.- Ion doble de (R)-N-metil-naltrexona, dihidrato. 6.- Procedimiento de preparación del compuesto ion doble de N-metil-naltrexona, tal como se define en una cualquiera de las reivindicaciones precedentes, que comprende la etapa que consiste en hacer reaccionar el metilsulfato de N-metil-naltrexona en solución acuosa con un agente alcalino elegido del grupo constituido por carbonato de sodio, carbonato de potasio, carbonato de calcio, carbonato de magnesio, carbonato de cesio, carbonato de estroncio y las mezclas de estos, para un pH del medio de reacción acuoso comprendido entre 7 y 10. 7.- Procedimiento de preparación del bromuro de N-metil-naltrexona, que comprende al menos las etapas que consisten en: (i) hacer reaccionar el metilsulfato de N-metil-naltrexona en solución acuosa con un agente alcalino elegido del grupo constituido por carbonato de sodio, carbonato de potasio, carbonato de calcio, carbonato de magnesio, carbonato de cesio, carbonato de estroncio y las mezclas de estos, para un pH del medio de reacción acuoso comprendido entre 7 y 10, y después (ii) hacer reaccionar el producto así obtenido con el ácido bromhídrico que se añade, para un pH del medio de reacción acuoso comprendido entre 0,5 y 5 y obtener así el bromuro de N-metil-naltrexona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0608286A FR2906252B1 (fr) | 2006-09-21 | 2006-09-21 | Procede de preparation d'halogenures de n-aklyl naltrexone |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6170362A2 true CO6170362A2 (es) | 2010-06-18 |
Family
ID=38016779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09028774A CO6170362A2 (es) | 2006-09-21 | 2009-03-19 | Procedimiento de preparacion de halogenuros de n-alquil-naltrexona |
Country Status (36)
Country | Link |
---|---|
US (2) | US7645880B2 (es) |
EP (1) | EP2069362B1 (es) |
JP (1) | JP5214615B2 (es) |
KR (1) | KR101434693B1 (es) |
CN (2) | CN101516892B (es) |
AR (1) | AR062918A1 (es) |
AU (1) | AU2007298855B2 (es) |
BR (1) | BRPI0718440A2 (es) |
CA (1) | CA2663509C (es) |
CL (1) | CL2007002711A1 (es) |
CO (1) | CO6170362A2 (es) |
CR (1) | CR10660A (es) |
DO (1) | DOP2011000307A (es) |
EA (1) | EA015426B1 (es) |
ES (1) | ES2531093T3 (es) |
FR (1) | FR2906252B1 (es) |
GT (1) | GT200900060A (es) |
HK (1) | HK1135389A1 (es) |
HN (1) | HN2009000503A (es) |
IL (1) | IL197402A (es) |
JO (1) | JO3023B1 (es) |
MA (1) | MA30793B1 (es) |
ME (1) | MEP10509A (es) |
MX (1) | MX2009003084A (es) |
MY (1) | MY148094A (es) |
NI (1) | NI200900035A (es) |
NO (1) | NO20091561L (es) |
NZ (1) | NZ575417A (es) |
PE (1) | PE20080867A1 (es) |
SV (1) | SV2009003192A (es) |
TN (1) | TN2009000080A1 (es) |
TW (1) | TWI465451B (es) |
UA (1) | UA96957C2 (es) |
UY (1) | UY30599A1 (es) |
WO (1) | WO2008034973A1 (es) |
ZA (1) | ZA200901846B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
WO2008138383A1 (de) * | 2007-05-16 | 2008-11-20 | Cilag Ag | Verfahren zur herstellung von n-methylnaltrexonbromid |
WO2009009292A2 (en) * | 2007-07-11 | 2009-01-15 | Mallinckrodt Inc. | Crystalline forms of naltrexone methobromide |
EP2019105A1 (en) * | 2007-07-19 | 2009-01-28 | Siegfried Ltd. | Process for the preparation of quaternary n-alkyl morphine or morphinane alkaloid derivatives |
US8080661B2 (en) * | 2008-09-30 | 2011-12-20 | Mallinckrodt Llc | Processes for the synthesis of tertiary amines |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
EP2398806A1 (en) * | 2009-02-23 | 2011-12-28 | Mallinckrodt LLC | (+)-morphinanium n-oxides and processes for their production |
US8436174B2 (en) * | 2009-02-23 | 2013-05-07 | Mallinckrodt Llc | (+)-morphinanium quaternary salts and processes for their production |
CN102325775A (zh) * | 2009-02-23 | 2012-01-18 | 马林克罗特公司 | (+)-6-羟基-吗啡喃或(+)-6-氨基-吗啡喃衍生物 |
NZ595591A (en) | 2009-04-24 | 2013-11-29 | Univ Brock | Processes for the preparation of morphinane and morphinone compounds |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
CN101845047B (zh) * | 2009-12-31 | 2011-12-07 | 南京臣功制药有限公司 | 一种溴甲基纳曲酮的制备方法 |
JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
US8580963B2 (en) | 2010-11-05 | 2013-11-12 | H. Lundbeck A/S | Method for the manufacturing of naltrexone |
SI2635586T1 (sl) | 2010-11-05 | 2017-07-31 | H. Lundbeck A/S | Metoda za izdelavo naltreksona |
WO2012138888A1 (en) | 2011-04-05 | 2012-10-11 | Alkermes, Inc. | Process for the synthesis of quaternary amine compounds |
JP2014526467A (ja) | 2011-09-08 | 2014-10-06 | マリンクロッド エルエルシー | 中間体の単離なしでのアルカロイドの調製 |
CN103172640A (zh) * | 2011-12-22 | 2013-06-26 | 天津康鸿医药科技发展有限公司 | 一种(r)-n-溴甲基纳曲酮的制备方法以及纳曲酮衍生物 |
AR090916A1 (es) | 2012-05-03 | 2014-12-17 | Lundbeck & Co As H | Metodo para la fabricacion de naltrexona |
CN105985348B (zh) * | 2015-02-12 | 2019-02-01 | 正大天晴药业集团股份有限公司 | 一种溴甲基纳曲酮的制备方法 |
CN106317064B (zh) * | 2015-06-30 | 2018-06-19 | 北大方正集团有限公司 | 溴甲纳曲酮的制备方法 |
KR102201609B1 (ko) * | 2019-04-19 | 2021-01-12 | 연성정밀화학(주) | 날데메딘의 제조방법 |
CN111777617A (zh) * | 2020-07-10 | 2020-10-16 | 华润三九医药股份有限公司 | 一种溴甲纳曲酮的精制方法 |
EP4225312A1 (en) | 2020-10-06 | 2023-08-16 | Scilex Holding Company | Oral delayed burst formulation of low-dose naltrexone or naloxone used for treating fibromyalgia and long covid |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
EP1562953B1 (en) * | 2002-11-08 | 2009-09-30 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
-
2006
- 2006-09-21 FR FR0608286A patent/FR2906252B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-19 MX MX2009003084A patent/MX2009003084A/es active IP Right Grant
- 2007-09-19 JP JP2009528751A patent/JP5214615B2/ja not_active Expired - Fee Related
- 2007-09-19 ME MEP-105/09A patent/MEP10509A/xx unknown
- 2007-09-19 KR KR1020097005731A patent/KR101434693B1/ko not_active IP Right Cessation
- 2007-09-19 TW TW096134967A patent/TWI465451B/zh not_active IP Right Cessation
- 2007-09-19 ZA ZA200901846A patent/ZA200901846B/xx unknown
- 2007-09-19 MY MYPI20091158A patent/MY148094A/en unknown
- 2007-09-19 UA UAA200903924A patent/UA96957C2/ru unknown
- 2007-09-19 NZ NZ575417A patent/NZ575417A/en not_active IP Right Cessation
- 2007-09-19 BR BRPI0718440-9A2A patent/BRPI0718440A2/pt not_active IP Right Cessation
- 2007-09-19 AU AU2007298855A patent/AU2007298855B2/en not_active Ceased
- 2007-09-19 EP EP07848250.2A patent/EP2069362B1/fr active Active
- 2007-09-19 CN CN2007800350747A patent/CN101516892B/zh not_active Expired - Fee Related
- 2007-09-19 CA CA2663509A patent/CA2663509C/fr not_active Expired - Fee Related
- 2007-09-19 CN CN2011101080743A patent/CN102225939A/zh active Pending
- 2007-09-19 ES ES07848250T patent/ES2531093T3/es active Active
- 2007-09-19 EA EA200970307A patent/EA015426B1/ru not_active IP Right Cessation
- 2007-09-19 WO PCT/FR2007/001516 patent/WO2008034973A1/fr active Application Filing
- 2007-09-20 CL CL200702711A patent/CL2007002711A1/es unknown
- 2007-09-20 JO JOP/2007/0399A patent/JO3023B1/ar active
- 2007-09-20 AR ARP070104157A patent/AR062918A1/es unknown
- 2007-09-20 PE PE2007001269A patent/PE20080867A1/es not_active Application Discontinuation
- 2007-09-20 UY UY30599A patent/UY30599A1/es not_active Application Discontinuation
-
2008
- 2008-03-17 US US12/049,607 patent/US7645880B2/en not_active Expired - Fee Related
-
2009
- 2009-03-04 IL IL197402A patent/IL197402A/en not_active IP Right Cessation
- 2009-03-10 TN TN2009000080A patent/TN2009000080A1/fr unknown
- 2009-03-11 CR CR10660A patent/CR10660A/es unknown
- 2009-03-12 GT GT200900060A patent/GT200900060A/es unknown
- 2009-03-18 HN HN2009000503A patent/HN2009000503A/es unknown
- 2009-03-19 CO CO09028774A patent/CO6170362A2/es active IP Right Grant
- 2009-03-19 SV SV2009003192A patent/SV2009003192A/es active IP Right Grant
- 2009-03-19 NI NI200900035A patent/NI200900035A/es unknown
- 2009-04-16 MA MA31789A patent/MA30793B1/fr unknown
- 2009-04-20 NO NO20091561A patent/NO20091561L/no not_active Application Discontinuation
- 2009-11-25 US US12/625,649 patent/US8288547B2/en not_active Expired - Fee Related
-
2010
- 2010-02-22 HK HK10101845.3A patent/HK1135389A1/xx not_active IP Right Cessation
-
2011
- 2011-10-07 DO DO2011000307A patent/DOP2011000307A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6170362A2 (es) | Procedimiento de preparacion de halogenuros de n-alquil-naltrexona | |
TW200801814A (en) | Positive resist composition and pattern formation method using the same | |
PE20030612A1 (es) | Benzoimidazoles | |
WO2008108409A1 (ja) | 第四級アンモニウム塩をゲスト化合物とする包接水和物 | |
TW200630359A (en) | (S)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate | |
AR071537A1 (es) | Proceso para preparar derivados de acido 2-amino-5-cianobenzoico | |
AR083100A1 (es) | Monohidrato de derivados de aza-adamantano | |
MX2017015606A (es) | Proceso para preparar 3-metilciclopentadecan-1,5-diona. | |
FR2836681B1 (fr) | Compose phosphocalcique modifie, composition injectable le contenant | |
WO2008035153A3 (en) | Process for the preparation of beta-lactam antibiotic | |
CR9424A (es) | Ibuprofeno solubilizado | |
MX342570B (es) | Proceso para producir granulos que comprende una o mas sales de agentes complejantes. | |
TW200628985A (en) | A chemically amplified positive resist composition | |
MY149706A (en) | Method for producing aqueous ?-sulfo fatty acid alkyl ester salt solution | |
AR029767A1 (es) | Procedimiento para la preparacion de compuestos de pirazolo (4, 3-d) pirimidin-7-onas-3-piridilsulfonilo y compuestos intermediarios utiles en dicho procedimiento. | |
TH135001B (th) | กรรมวิธีสำหรับการเตรียม n-แอลคิลแนลเทรกโซนเฮไลด์ | |
TH135001A (th) | กรรมวิธีสำหรับการเตรียม n-แอลคิลแนลเทรกโซนเฮไลด์ | |
DOP2009000041A (es) | Procedimiento de preparacion de halogenuros de n-alquil-naltrexona | |
RU2007149526A (ru) | Гидраты солей щелочноземельных металлов и ирбесартана и их получение | |
RU2016101466A (ru) | Способ снижения концентрации ионов стронция | |
WO2007129184A3 (en) | An improved process for the preparation of phenytoin sodium | |
EA200500747A1 (ru) | Средство для дезинфекции | |
ATE340821T1 (de) | Carboxymethylcellulose mit verbesserter löslichkeit im wasser | |
RU2011151667A (ru) | Способ стабилизации щелочного раствора пероксида водорода | |
TH96053B (th) | เกลือไฮโดรเจนซัลเฟตชนิดใหม่ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |